FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR
The FDA approved a 150-mg dose of secukinumab (Cosentyx, Novartis) for polymyalgia rheumatica (PMR), making it the first anti-IL-17 biologic for this condition. The approval was based on the phase 3 REPLENISH trial, which showed higher remission rates with secukinumab plus a glucocorticoid taper compared to the taper alone. According to Novartis, this is the 11th US indication for secukinumab.
How this was made

The 30-second read
Why it matters
A first and only FDA approval for anti-IL-17 biologic therapy in PMR, supported by phase 3 REPLENISH results, creates a new commercial indication and may improve investor expectations for Cosentyx’s growth trajectory.
Market read
Traders can treat this as a regulatory catalyst for Novartis’ Cosentyx franchise, with potential sentiment lift from a first-in-class PMR label expansion.
What to watch
The article highlights efficacy and steroid reduction, but does not quantify pricing, reimbursement, or expected patient share, which are key drivers of near-term financial impact.
Background
Polymyalgia rheumatica (PMR) is commonly treated with long-term glucocorticoids, which carry significant risks; secukinumab is an anti-IL-17A monoclonal antibody already approved for other inflammatory conditions.
Ticker impact
FDA approved secukinumab (Cosentyx) for PMR, expanding Novartis’ IL-17 biologic label and adding a new US indication.
Likely positive bias as investors price in label expansion and reduced steroid burden for PMR patients.
The article is a first-in-class FDA approval for a new indication, supported by phase 3 REPLENISH efficacy and safety data, which is typically market-moving for the sponsor’s product franchise.
Market effects
Strengthens the IL-17 biologics competitive narrative in inflammatory rheumatology and may shift expectations for steroid-sparing regimens.
Primarily US regulatory-driven, but can influence global payer and prescriber expectations for PMR treatment.
Could accelerate adoption discussions in other markets where Cosentyx is already approved for related inflammatory diseases.
Counterpoint
PMR is a steroid-dependent standard of care, so uptake may be slower than efficacy headlines suggest due to prescribing inertia, payer prior authorization, and long-term safety monitoring.
Key entities
- drugSecukinumab (Cosentyx)
Fully human monoclonal antibody that selectively inhibits IL-17A, now FDA-approved for PMR at a 150 mg dose.
- companyNovartis
Sponsor of Cosentyx; president US quoted on the approval and expansion to an 11th US indication.
- clinical_trialREPLENISH trial
Phase 3 study in recently relapsed PMR comparing secukinumab plus prednisone taper versus placebo plus taper.



